Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00457587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

  1. Notable

    Primary completion date: Dec 2027 to Dec 2029

    Completion date: Dec 2028 to Dec 2030

    Study Statusv18

  2. Notable

    Primary completion date: Dec 2025 to Dec 2027

    Trial status: Recruiting to Active, Not Recruiting; Enrollment target: estimated 200 to confirmed 150; Completion date: Dec 2026 to Dec 2028; and 1 more

    Show all 5 changes in this update
    • Notable Primary completion date: Dec 2025 to Dec 2027
    • Minor Trial status: Recruiting to Active, Not Recruiting
    • Minor Enrollment target: estimated 200 to confirmed 150
    • Minor Completion date: Dec 2026 to Dec 2028
    • Minor Site details revised

    Study Status, Study Design, Contacts/Locationsv17

  3. Minor

    Study Status

    Re-verified, no change to tracked fields

    v16

  4. Notable

    Primary completion date: Dec 2023 to Dec 2025

    Completion date: Dec 2024 to Dec 2026

    Study Statusv15

  5. Notable

    Primary completion date: Dec 2025 to Dec 2023

    Completion date: Dec 2026 to Dec 2024

    Study Status, Contacts/Locationsv14

Show 12 earlier versions

  1. Notable

    Trial status: Active, Not Recruiting to Recruiting

    Enrollment target: 70 to 200; Primary completion date: Dec 2011 to Dec 2025; Completion date: Dec 2018 to Dec 2026; and 1 more

    Show all 5 changes in this update
    • Notable Trial status: Active, Not Recruiting to Recruiting
    • Notable Enrollment target: 70 to 200
    • Notable Primary completion date: Dec 2011 to Dec 2025
    • Minor Completion date: Dec 2018 to Dec 2026
    • Minor Site details revised

    Study Status, Study Design, Contacts/Locations, Referencesv13

  2. Minor

    Completion date: Dec 2017 to Dec 2018

    Study Statusv12

  3. Minor

    Completion date: Dec 2016 to Dec 2017

    Study Statusv11

  4. Minor

    Study Status

    Re-verified, no change to tracked fields

    v10

  5. Minor

    Completion date: Dec 2013 to Dec 2016

    Study Status, Outcome Measuresv9

  6. Notable

    Primary completion date changed from estimate of Dec 2010 to Dec 2011

    Completion date: Dec 2011 to Dec 2013

    Study Status, Sponsor/Collaborators, Study Designv8

  7. Minor

    Trial status: Recruiting to Active, Not Recruiting

    Primary completion date: Jun 2010 to Dec 2010; Completion date: Dec 2010 to Dec 2011; Site details revised

    Study Status, Eligibility, Contacts/Locationsv7

  8. Minor

    Study Status

    Re-verified, no change to tracked fields

    v6

  9. Notable

    Phase: Early Phase 1 to Not specified

    Primary completion date: Jun 2010; Completion date: Dec 2009 to Dec 2010; Site contact updated

    Study Status, Study Design, Arms and Interventions, Contacts/Locationsv5

  10. Minor

    3 amendments

    3 re-verifications since 2007-04-09, no change to tracked fields

    v2-v4

  1. Minor

    Study First Submitted

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.
Trial Details
NCT Number NCT00457587
Lead Sponsor University of Wuerzburg
Collaborators: Deutsche Krebshilfe e.V., Bonn (Germany)
Conditions Adrenocortical Carcinoma, Cushing's Syndrome
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov